139 related articles for article (PubMed ID: 27473264)
1. T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin.
Raspollini MR; Luque RJ; Menendez CL; Bollito E; Brunelli M; Martignoni G; Montironi R; Cheng L; Blanca A; Baroni G; Minervini A; Lopez-Beltran A
Hum Pathol; 2016 Nov; 57():78-84. PubMed ID: 27473264
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
3. A proposed score for assessing progression in pT1 high-grade urothelial carcinoma of the bladder.
Raspollini MR; Minervini A; Lapini A; Lanzi F; Rotellini M; Baroni G; Carini M
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):218-27. PubMed ID: 22820663
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973).
March-Villalba JA; Ramos-Soler D; Soriano-Sarrió P; Hervás-Marín D; Martínez-García L; Martínez-Jabaloyas JM
Urol Oncol; 2019 Feb; 37(2):158-165. PubMed ID: 30446453
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma.
Breyer J; Gierth M; Shalekenov S; Aziz A; Schäfer J; Burger M; Denzinger S; Hofstädter F; Giedl C; Otto W
World J Urol; 2016 May; 34(5):709-16. PubMed ID: 26394624
[TBL] [Abstract][Full Text] [Related]
6. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.
Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC
Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of survivin and DNA topoisomerase IIα in diffuse and anaplastic astrocytomas.
Varughese RK; Skjulsvik AJ; Torp SH
Pathol Res Pract; 2017 Apr; 213(4):339-347. PubMed ID: 28214203
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma: Association with poor clinical outcome and potential therapeutic target.
Go H; Kim PJ; Jeon YK; Cho YM; Kim K; Park BH; Ku JY
Eur J Cancer; 2015 Sep; 51(14):1937-45. PubMed ID: 26238015
[TBL] [Abstract][Full Text] [Related]
9. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions.
Shi J; Liu H; Wilkerson M; Huang Y; Meschter S; Dupree W; Schuerch C; Lin F
Hum Pathol; 2007 Sep; 38(9):1335-44. PubMed ID: 17512033
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
Chang WC; Chang YH; Pan CC
Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
[TBL] [Abstract][Full Text] [Related]
12. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
[TBL] [Abstract][Full Text] [Related]
13. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.
Kucukgoz Gulec U; Gumurdulu D; Guzel AB; Paydas S; Seydaoglu G; Acikalin A; Khatib G; Zeren H; Vardar MA; Altintas A
Arch Gynecol Obstet; 2014 Feb; 289(2):393-8. PubMed ID: 23974278
[TBL] [Abstract][Full Text] [Related]
14. Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder.
Yin W; Chen N; Zhang Y; Zeng H; Chen X; He Y; Wang X; Zhou Q
Mod Pathol; 2006 Nov; 19(11):1487-97. PubMed ID: 16892011
[TBL] [Abstract][Full Text] [Related]
15. Aurora-A/STK-15 is differentially expressed in the micropapillary variant of bladder cancer.
Compérat E; Roupret M; Conort P; Chartier-Kastler E; Bitker MO; Richard F; Capron F; Haertig A; Cussenot O; Camparo P
Urol Int; 2009; 82(3):312-7. PubMed ID: 19440020
[TBL] [Abstract][Full Text] [Related]
16. Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.
Klaassen Z; Kamat AM; Kassouf W; Gontero P; Villavicencio H; Bellmunt J; van Rhijn BWG; Hartmann A; Catto JWF; Kulkarni GS
Eur Urol; 2018 Nov; 74(5):597-608. PubMed ID: 30017405
[TBL] [Abstract][Full Text] [Related]
17. Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder.
Reis LO; Taheri D; Chaux A; Guner G; Mendoza Rodriguez MA; Bivalacqua TJ; Schoenberg MP; Epstein JI; Netto GJ
Hum Pathol; 2016 Jan; 47(1):20-5. PubMed ID: 26520419
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEx C, and p16INK4a/ProEx C in cervical squamous intraepithelial lesions.
Boucher J; Anku-Bertholet C; Temmar R; Pelmus M
Hum Pathol; 2009 Jun; 40(6):904-5; author reply 905-6. PubMed ID: 19442790
[No Abstract] [Full Text] [Related]
19. Evaluation of different p16 immunostaining methods and the prognostic role of p16/Ki-67 combined expression in non-muscle invasive bladder cancers.
Özyalvaçli G; Özyalvaçli ME; Astarci HM; Boran Ç; Yeşil C; Üyetürk U; Aktaș G
Pol J Pathol; 2015 Mar; 66(1):57-66. PubMed ID: 26017881
[TBL] [Abstract][Full Text] [Related]
20. Clinical Use of Tumor Markers for the Detection and Prognosis of Bladder Carcinoma: A Comparison of CD44, Cytokeratin 20 and Survivin.
Yikilmaz TN; Dirim A; Ayva ES; Ozdemir H; Ozkardes H
Urol J; 2016 Jun; 13(3):2677-83. PubMed ID: 27351322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
